Abstracts tagged "Administrative Data"

Abstract Number: 0768 • ACR Convergence 2021
Poverty and Length of Stay in Children Hospitalized with Pediatric Systemic Lupus Erythematosus: An Analysis of the 2016 Kids’ Inpatient Database
William Soulsby, Erica Lawson and Matthew Pantell, University of California San Francisco, San Francisco, CA
Background/Purpose: Prior studies have demonstrated alarming health disparities in adult patients with SLE, including higher disease severity and activity among Hispanic and Black patients. Pediatric…
Abstract Number: 0128 • ACR Convergence 2021
Increased Risk of Major Adverse Cardiac Events in Patients with Systemic Lupus Erythematosus After Non-Cardiac Surgery
Sebastian Bruera¹, Xiudong Lei², Brandon Blau¹, Hui Zhao², Anita Deswal², Jinoos Yazdany³, Sharon Giordano² and Maria Suarez-Almazor², ¹Baylor College of Medicine, Houston, TX, ²University of Texas MD Anderson Cancer Center, Houston, TX, ³University of California San Francisco, San Francisco, CA
Background/Purpose: The association between systemic lupus erythematosus (SLE) and cardiovascular disease has been well-studied. Cardiovascular disease is a risk factor for major adverse cardiac events…
Abstract Number: 0981 • ACR Convergence 2021
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
David Singer¹, Philippe Thompson-Leduc², Sara Poston¹, Deepshekhar Gupta³, Wendy Cheng⁴, Siyu Ma¹, Francesca Devine⁵, Alexandra Enrique³, Mei Sheng Duh⁶ and Jeffrey Curtis⁷, ¹GlaxoSmithKline, Philadelphia, PA, ²Analysis Group, Inc., Montréal, QC, Canada, ³Analysis Group, Inc., Menlo Park, CA, ⁴Analysis Group, Inc., Boston, MA, ⁵Analysis Group, Inc., New York, NY, ⁶Analysis Group, Boston, MA, ⁷Division of Clinical Immunology and Rheumatology, Department of Medicine, Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL

Background/Purpose: Herpes zoster (HZ) is a disease caused by the reactivation of the varicella-zoster virus in previously infected individuals and is characterized by a painful…
Abstract Number: 0129 • ACR Convergence 2021
Real-World Flare Rates and Progression by Treatment Settings Among the Commercially-Insured Systemic Lupus Erythematosus Population in the U.S
Sandra Sze-jung Wu¹, Allison Perry², Helen Varker², Richard Bizier², Joseph Tkacz² and Robert Ortmann³, ¹AstraZeneca, Wilmington, DE, ²IBM Watson Health, Bethesda, MD, ³AstraZeneca, Greenwood, IN
Background/Purpose: The clinical presentation of systemic lupus erythematosus (SLE) is complicated, as patients cycle through periods of active disease (flares) and remission. To establish the…
Abstract Number: 1267 • ACR Convergence 2021
Frailty and Emergency Department Utilization in Systemic Lupus Erythematosus: An Administrative Claims Data Analysis
Sarah Lieber¹, Iris Navarro-Milln², Musarrat Nahid², Mangala Rajan², Sebastian Sattui¹ and Lisa Mandl¹, ¹Hospital for Special Surgery, New York, NY, ²Weill Cornell Medicine, New York, NY
Background/Purpose: Emergency department (ED) utilization is associated with worse quality of care and health-related quality of life (HRQoL) in systemic lupus erythematosus (SLE). While frailty…
Abstract Number: 0130 • ACR Convergence 2021
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients: Real World Observation Across Disease Severity and Payer Channels in the U.S
Joseph Tkacz¹, Allison Perry¹, Helen Varker¹, Richard Bizier¹, Robert Ortmann² and Sandra Sze-jung Wu³, ¹IBM Watson Health, Bethesda, MD, ²AstraZeneca, Greenwood, IN, ³AstraZeneca, Wilmington, DE
Background/Purpose: Current literature characterizing the economic and clinical burden of systemic lupus erythematosus (SLE) is outdated and often does not consider SLE disease severity, which…
Abstract Number: 1292 • ACR Convergence 2021
Systemic Lupus Erythematous Readmissions Has Reduced in the Last Decade in the United States: A 9- year Longitudinal Study of the Nationwide Readmission Database
Ehizogie Edigin¹, Precious Eseaton², Chinenye Osuorji³, Ajayi Temitope⁴, Oluwafeyi Adedoyin⁵, Nneka Chukwu⁶ and Augustine Manadan⁷, ¹Internal Medicine, John H Stroger Jr. Hospital of Cook County, Chicago, IL, ²University of Benin, Benin, Nigeria, ³Internal Medicine, Burrell College of Osteopathic Medicine, Las Cruces, NM, ⁴Internal Medicine, University of Buffalo, Buffalo, NY, ⁵Internal Medicine, Englewood Hospital and Medicine Center, Englewood, NJ, ⁶Nuvance Health Internal Medicine Residency, Poughkeepsie, NY, ⁷Rush University Medical Center, Chicago, IL
Background/Purpose: Longitudinal data on trends of Systemic Lupus Erythematous (SLE) readmissions is scarce. Our study aims to study trends of 30-day readmissions of patients admitted…
Abstract Number: 0134 • ACR Convergence 2021
Systemic Lupus Erythematosus Is a Risk Factor for Mortality in Older Patients with Early-Stage Breast Cancer
Sebastian Bruera¹, Xiudong Lei², Xerxes Pundole², Hui Zhao², Sharon Giordano², Surabhi Vinod¹ and Maria Suarez-Almazor², ¹Baylor College of Medicine, Houston, TX, ²University of Texas MD Anderson Cancer Center, Houston, TX
Background/Purpose: Women with systemic lupus erythematosus (SLE) who develop breast cancer (BC), may receive different therapies (e.g. radiation) than women with BC who do not…
Abstract Number: 1713 • ACR Convergence 2021
Risk of Serious Infections in Offspring Exposed in Utero to Ustekinumab or Vedolizumab
Jonah Gorodensky¹, Sasha Bernatsky¹, Waqqas Afif¹, Yvan St-Pierre², Kristian Filion¹ and Evelyne Vinet³, ¹McGill University, Montréal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montréal, QC, Canada, ³McGill University Health Centre, Mont Royal, QC, Canada
Background/Purpose: Ustekinumab, an IL-12/23 inhibitor, is indicated in adult patients with inflammatory bowel disease (IBD), psoriasis (PsO), and psoriatic arthritis (PsA) and vedolizumab, an α4β7…
Abstract Number: 0143 • ACR Convergence 2021
Economic and Healthcare Resource Use Burden of Systemic Sclerosis
Dinesh Khanna¹, Dan Furst², Justin Li³, Qian Meng⁴, Tamara Lesperance⁵, Kenyatta Peoples⁶, Farah Ali⁵, Brian LaMoreaux⁵ and Stephanie Taylor⁷, ¹University of Michigan, Ann Arbor, MI, ²University of California Los Angeles, Los Angeles, CA, ³Trinity Partners, Waltham, MA, ⁴Trinity Life Sciences, Waltham, MA, ⁵Horizon Therapeutics plc, Deerfield, IL, ⁶Horizon Therapeutics plc, Lake Forest, IL, ⁷Horizon Therapeutics plc, Whitehouse Station, NJ
Background/Purpose: The clinical burden of systemic sclerosis (SSc) is substantial and typically characterized by progressive skin, gastrointestinal, pulmonary, and cardiovascular complications and premature death. The…
Abstract Number: 1896 • ACR Convergence 2021
Initial Results from the Implementation of a National Hydroxychloroquine Safe Prescribing Dashboard Within the Veterans Health Administration
Anna Montgomery¹, Gary Tarasovsky², Iziegbe Ehiorobo³, Mary Whooley², Jennifer Barton⁴, Khushboo Sheth⁵, Kimberly Reiter⁶, Meredith Keller⁷, Lorinda Chung⁸, Lori Bennett⁹, Jo Dana², Elizabeth Wahl¹⁰ and Gabriela Schmajuk³, ¹Department of Veterans Affairs, Tiburon, CA, ²San Francisco VA Healthcare System, San Francisco, CA, ³University of California San Francisco, San Francisco, CA, ⁴Portland VA Healthcare System, Portland, OR, ⁵Stanford University/VA Palo Alto, Atherton, CA, ⁶Raymond G Murphy VA Medical Center, Albuquerque, NM, ⁷New Mexico VA Health Care System, Albuquerque, NM, ⁸Stanford University, Palo Alto, CA, ⁹Charleston VAHCS, Charleston, SC, ¹⁰VA Puget Sound Health Care System, Seattle, WA
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used medication for patients with lupus erythematosus, rheumatoid arthritis, and other autoimmune conditions. However, HCQ daily doses of ≥…
Abstract Number: 0144 • ACR Convergence 2021
Healthcare Utilization and Costs Following Kawasaki Disease in Ontario, Canada
Cal Robinson¹, Rahul Chanchlani², Anastasia Gayowsky³, Elizabeth Darling², Hsien Seow² and Michelle Batthish², ¹The Hospital for Sick Children, Hamilton, ON, Canada, ²McMaster University, Hamilton, ON, Canada, ³ICES, Hamilton, ON, Canada
Background/Purpose: The incidence of Kawasaki Disease (KD) has increased by nearly 50% in Ontario, Canada over the past two decades. Little is known about the…
Abstract Number: 1923 • ACR Convergence 2021
Has the Incidence of Total Joint Arthroplasty in Rheumatoid Arthritis Decreased in the Era of Biologics Use? A Population-based Incident Cohort Study 1995–2015
Vivienne Zhou¹, Diane Lacaille¹, Na Lu², Jacek Kopec³, Don Garbuz¹, Yi Qian⁴, J. Antonio Avina-Zubieta¹, John Esdaile² and Hui Xie¹, ¹Arthritis Research Canada, Richmond, BC, Canada, ²Arthritis Research Canada, Vancouver, BC, Canada, ³University of British Columbia, Richmond, BC, Canada, ⁴University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Total joint arthroplasty (TJA) is an undesirable long-term outcome of rheumatoid arthritis (RA) due to joint damage from uncontrolled inflammation. Although biological disease-modifying anti-rheumatic…
Abstract Number: 0259 • ACR Convergence 2021
JIA Diagnoses and Trends from 2006-2019: Has the U.S. ICD-9-to-ICD-10 Transition Created Coding Artifacts?
Daniel Horton¹, Lauren Parlett², Cecilia Huang³, Stephen Crystal⁴, Amy Davidow⁵, Tobias Gerhard⁶, Carlos Rose⁷, Kevin Haynes² and Brian Strom⁸, ¹Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ²HealthCore, Wilmington, DE, ³Rutgers Institute for Health, New Brunswick, NJ, ⁴Rutgers School of Social Work, New Brunswick, NJ, ⁵Rutgers School of Public Health, New Brunswick, NJ, ⁶Ernst Mario School of Pharmacy, New Brunswick, NJ, ⁷Thomas Jefferson University, Wilmington, DE, ⁸Rutgers Biomedical and Health Sciences, Newark, NJ
Background/Purpose: JIA is the most common rheumatic disease of childhood, but recent data on diagnostic trends in the US are lacking. Furthermore, the impact of…
Abstract Number: 1931 • ACR Convergence 2021
The Burden of Thirty-day Readmission and Independent Predictors of Readmission in Patients with Systemic Lupus Erythematosus: A Nationwide Analysis
Ashu Acharya¹, Saffa Iftikhar¹, Yasmin Khader¹, Sachit Sharma¹, Joan N Gekonde¹, Rawish Fatima¹, Cameron J Burmeister¹ and Nezam Altorok², ¹University of Toledo Medical Center, Toledo, OH, ²University of Toledo, Toledo, OH
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic immune-mediated disease with 20-25% patients needing hospital admission annually. Early readmissions add to the clinical and economic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].